Triax

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Nov 1, 2024FDAMinocin — EMROSI

May 28, 2020FDAMinocin — ZILXI

Oct 18, 2019FDAMinocin — AMZEEQ

May 8, 2017FDAMinocin — MINOLIRA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

7 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Minocin3 patentsMar 7, 2027 Minocin13 patentsOct 1, 2030 Minocin4 patentsMay 12, 2031 MinocinOct 16, 2032 MinocinApr 7, 2036 Minocin2 patentsSep 8, 2037 Minocin4 patentsJan 7, 2039

Regulatory

Regulatory Timeline

19824 events

FDAAug 10

Minocin — MINOCYCLINE HYDROCHLORIDE

Application NDA050451 (NDA)

FDAJan 1

Minocin — MINOCIN

Application NDA050445 (NDA)

FDAJan 1

Minocin — MINOCIN

Application NDA050444 (NDA)

FDAJan 1

Minocin — MINOCIN

Application NDA050315 (NDA)

19901 event

FDAMay 31

Minocin — MINOCIN

Application NDA050649 (NDA)

20011 event

FDAFeb 16

Minocin — ARESTIN

Application NDA050781 (NDA)

20061 event

FDAMay 8

Minocin — SOLODYN

Application NDA050808 (NDA)

20121 event

FDAJul 11

Minocin — XIMINO

Application NDA201922 (NDA)

20171 event

FDAMay 8

Minocin — MINOLIRA

Application NDA209269 (NDA)

20191 event

FDAOct 18

Minocin — AMZEEQ

Application NDA212379 (NDA)

20201 event

FDAMay 28

Minocin — ZILXI

Application NDA213690 (NDA)

20241 event

FDANov 1

Minocin — EMROSI

Application NDA219015 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)